Theresa W. Guilbert, MD, MS
- Director, Asthma Center
- Professor, UC Department of Pediatrics
- theresa.guilbert@cchmc.org
- Board Certified
About
Biography
As a lung specialist, I care for children who wheeze early in their lives and those with severe asthma. I enjoy working with children and their families, and nothing gives me more satisfaction than to help a child control their asthma symptoms so they can be the best version of themselves.
My approach is to listen carefully to the child's story, make sure that I understand it accurately, and ask clarifying questions. Then, working as a team with the child and family, we develop an effective management plan that the family feels comfortable initiating. We reassess how well the child is doing as a team to decide whether to continue that plan or adapt it to improve the child's life.
I have over 20 years of experience in treating children with pulmonary diseases, interpreting lung function and imaging studies, and participating in National Institutes of Health (NIH)-funded, multicenter clinical trials. These trials seek ways to prevent asthma in preschool children and to improve asthma management in older children. I direct the Asthma Center at Cincinnati Children’s, and I am passionate about learning how to prevent or reverse asthma and how to manage it better once it develops.
I have served as chair or member of several national committees, such as the American Academy of Pediatrics, the American Board of Pediatrics and the American Thoracic Society. I have also been on the steering committees of several NIH-sponsored, multicenter clinical networks that design and conduct asthma research studies in children.
In my free time, I enjoy camping, hiking, boating and traveling with my family. I am also a Pilates and yoga enthusiast.
MD: University of Minnesota, Minneapolis, MN, 1992.
Residency: Pediatrics, University of Minnesota, Minneapolis, MN.
Fellowship: Pediatric Pulmonology, University of Colorado, Denver, CO.
MS: Epidemiology, University of Arizona, Tucson, AZ, 2007.
Interests
Preschool wheezing; difficult-to-control asthma
Services and Specialties
Interests
Early life risk factors, exposures, and environment interactions; early childhood asthma; recurrent wheezing; clinical electronic medical data
Research Areas
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Evaluating the Impact of the COVID-19 Pandemic on Pediatric Asthma Incidence. The Journal of Allergy and Clinical Immunology: in Practice. 2025; 13:S2213-2198(25)00477-5.
Consensus outcomes between health professionals and parents for oral corticosteroids in treating preschool wheeze: a multi-national survey and nominal group technique study. Sexually Transmitted Infections. 2025; 110:521-527.
Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High-Dose ICS in Children With Uncontrolled Moderate-to-Severe Type 2 Asthma. Pediatric Pulmonology. 2025; 60:e71197.
Performance of the Pediatric Asthma Impairment and Risk Questionnaire (Peds-AIRQ) in Assessing Control for Children With Asthma Aged 5 to 11 Years. American Journal of Respiratory and Critical Care Medicine. 2025; 211:a1288.
Current Practices Among 13 Severe Pediatric Asthma Programs in the United States. American Journal of Respiratory and Critical Care Medicine. 2025; 211:a2249.
Dupilumab Reduces Exacerbations and Improves Asthma Control in Children Regardless of Asthma Duration. American Journal of Respiratory and Critical Care Medicine. 2025; 211:a1374.
Epinephrine Prescription and Post-injection Monitoring Practices for Biologic Therapies in Pediatric Severe Asthma Clinics: A Multicenter Survey Analysis. American Journal of Respiratory and Critical Care Medicine. 2025; 211:a2264.
Performance of the Pediatric Asthma Impairment and Risk Questionnaire (Peds-AIRQ) in Assessing Control Relative to the Pediatric Quality of Life Inventory (PedsQL) and Patient Impression of Control. American Journal of Respiratory and Critical Care Medicine. 2025; 211:a5022.
Dupilumab plus medium-dose inhaled corticosteroid improves outcomes compared with placebo plus high-dose inhaled corticosteroid in pediatric patients with uncontrolled asthma. Klinische Paediatrie: Zeitschrift fuer Klinik und Praxis. 2025; 237:s2.
Rémission clinique avec le dupilumab chez les enfants atteints d’asthme de type 2 non contrôlé, modéré à sévère. 2025; 8:84.
From the Blog
Podcast | Understanding Asthma: Risk Factors, Triggers and Treatments
Theresa W. Guilbert, MD, MS8/2/2024
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey